<DOC>
	<DOCNO>NCT00568607</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability combination chemotherapy DICE patient NK/T cell lymphoma .</brief_summary>
	<brief_title>Study Combination Regimen Dexamethasone Ifosfamide Cisplatin Etoposide Patients With NK/T Cell Lymphoma</brief_title>
	<detailed_description>Patients NK/T cell lymphoma usually bad prognosis . These patient treat successfully conventional chemotherapy CHOP.The investigator trial evaluate efficacy tolerability combination chemotherapy DICE patient NK/T cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Age range 1875 year old Histological confirm NK/T cell lymphoma ECOG performance status le 2 Life expectancy 3 month None major drug trial ( IFO , VP16 , DDP ) previously use Normal laboratory value : hemoglobin &gt; 80 g/dl , neutrophil &gt; 2×109/L , platelet &gt; 100×109/L , serum creatine &lt; 1.5×upper limitation normal ( ULN ) , serum bilirubin &lt; 1.5×ULN , ALT AST &lt; 2.5×ULN Pregnant lactate woman Serious uncontrolled disease intercurrent infection The evidence CNS metastasis History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>NK/T cell lymphoma</keyword>
	<keyword>Response Rate</keyword>
	<keyword>TTP</keyword>
	<keyword>OS</keyword>
	<keyword>Toxicities</keyword>
</DOC>